Elapegademase-lvlr ( DrugBank: Elapegademase, Elapegademase-lvlr )


1 disease
IDDisease name (Link within this page)Number of trials
65Primary immunodeficiency1

65. Primary immunodeficiency


Clinical trials : 482 Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03878069
(ClinicalTrials.gov)
June 25, 201912/3/2019Registry Study of Revcovi Treatment in Patients With ADA-SCIDSingle Arm, Open-Label, Multicenter, Registry Study of Revcovi (Elapegademase-lvlr) Treatment in ADA-SCID Patients Requiring Enzyme Replacement TherapyAdenosine Deaminase Deficiency;Severe Combined ImmunodeficiencyBiological: elapegademase-lvlrChiesi Farmaceutici S.p.A.NULLRecruitingN/A65 YearsAll20United States